Navigation Links
FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age
Date:3/24/2011

SILVER SPRING, Md., March 24, 2011 /PRNewswire-USNewswire/ -- The Food and Drug Administration (FDA) today approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

In the United States shingles affects approximately 200,000 healthy people between the ages of 50 and 59, per year. It is a disease caused by the varicella-zoster virus, which is a virus in the herpes family and the same virus that causes chickenpox. After an attack of chickenpox, the virus lies dormant in certain nerves in the body. For reasons that are not fully understood, the virus can reappear in the form of shingles, more commonly in people with weakened immune systems and with aging.

"The likelihood of shingles increases with age. The availability of Zostavax to a younger age group provides an additional opportunity to prevent this often painful and debilitating disease," said Karen Midthun, M.D., director of FDA's Center for Biologics Evaluation and Research.

Shingles is characterized by a rash of blisters, which generally develop in a band on one side of the body and can cause severe pain that may last for weeks, and in some people, for months or years after the episode.

Approval was based on a multicenter study conducted in the United States and four other countries in approximately 22,000 people who were 50-59 years of age. Half received Zostavax and half received a placebo. Study participants were then monitored for at least one year to see if they developed shingles. Compared with placebo, Zostavax reduced the risk of developing shingles by approximately 70 percent.

The most common side effects observed in the study were redness, pain and swelling at the site of injection, and headache.

Zostavax was originally approved on May 26, 2006, for the prevention of shingles in individuals 60 years of age and older.

Zostavax is manufactured by Merck & Co. Inc., of Whitehouse Station, New Jersey.

For more information:

Zostavax Product Page

http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm136941.htm

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Gadavist for Central Nervous System Scans
2. U.S. FDA Approves Bayers Gadavist™ (Gadobutrol) Injection for MRI of the Central Nervous System
3. FDA Approves Device to Maintain Blood Flow During Artery Bypass Brain Surgery
4. FDA Approves BENLYSTA® for Lupus in Breakthrough for Millions of Sufferers
5. FDA Approves Revised Alphanate® Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD
6. UPDATE: FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
7. FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
8. FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
9. FDA Approves Edarbi to Treat High Blood Pressure
10. FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
11. FDA Approves Product to Prevent Bleeding in People With Rare Genetic Defect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Direct-to-consumer digital marketing ... and 65% increase in consumable sales, quarter-over-quarter ... DRIO ), a leader in digital health ... Dario™ Blood Glucose Monitoring System, an all-in-one diabetes meter, ... and minimally invasive smart diabetes management solution. ...
(Date:1/23/2017)... The American Pharmacists Association (APhA) is excited ... Medically Underserved Areas Enhancement Act (H.R. 592) ... was previously introduced in the 114 th session ... through pharmacists and their patient care services. ... (R-KY), G.K. Butterfield (D-NC), Tom ...
(Date:1/23/2017)... New York , January 23, 2017 ... Non-Invasive Prenatal Testing Market was valued at US$0.53 bn in ... expanding at a strong 17.50% CAGR between 2014 and 2022. The ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... Non-invasive ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... with the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education ... of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high ...
(Date:1/23/2017)... ... , ... “Crossing the Bar”: a moving and eloquent drama depicting the ... Bar” is the creation of published author, Charlotte Hotte, a North Carolina native, a ... inspiration of the book to her sister, Denise, wishes to acknowledge her savior, Jesus ...
(Date:1/23/2017)... ... ... “Some Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the ... of published author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He ... nineteen, a pastor for over fifteen years. He is a graduate of N.C. College ...
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian ... world, recently met with big-name retail buyers at the January ECRM Trade Show in ... and uses the utmost safety standards in all of its creations to help create ...
(Date:1/21/2017)... ... , ... Caronlab Australia, an Australian company known for health and beauty products ... SC, where it benefited from outstanding meetings with major retail buyers. , Caron Labs ... At this trade show, the company had the chance to demonstrate its products and ...
Breaking Medicine News(10 mins):